Cervical Dystonia Market Report and Forecast 2024-2032

The cervical dystonia market size is projected to grow at a compound annual growth rate (CAGR) of 5.8% during the forecast period of 2024-2032. The key drivers of the market growth are the increasing awareness and diagnosis of cervical dystonia, the rising demand for botulinum toxin injections, the development of novel therapies and devices, and the growing geriatric population.

Cervical dystonia, also known as spasmodic torticollis, is a rare and chronic condition that affects the muscles of the neck, causing them to twist and tilt in abnormal postures. It can cause pain, discomfort, and difficulty in performing daily activities. The exact cause of cervical dystonia is unknown, but it may be related to genetic factors, environmental triggers, or brain abnormalities. The prevalence of cervical dystonia is estimated to be between 57 and 280 per million people worldwide, with a higher incidence in women and older age groups. The diagnosis of cervical dystonia is based on clinical examination and medical history, and the treatment options include oral medications, botulinum toxin injections, surgery, and physical therapy.

Cervical Dystonia Epidemiology
The epidemiology of cervical dystonia in the market is influenced by several factors, such as the geographic distribution, the age and gender distribution, the diagnostic criteria, and the data sources. According to a systematic review and meta-analysis by Epidemiology International, the global prevalence of cervical dystonia was 158.67 per million people, with a 95% confidence interval (CI) of 94.38-222.96, based on 29 studies from 16 countries. The prevalence was higher in Europe (193.77 per million) than in North America (120.77 per million) and Asia (86.43 per million). The prevalence was also higher in women (228.77 per million) than in men (88.57 per million), and in older age groups (40-59 years: 235.96 per million; 60-79 years: 392.92 per million) than in younger age groups (20-39 years: 59.82 per million; < 20 years: 10.59 per million). The diagnosis of cervical dystonia was based on various criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), the International Classification of Diseases (ICD), or the clinical judgment of physicians. The data sources included population-based surveys, hospital-based registries, or insurance databases.

Cervical Dystonia Market Drivers and Constraints

• Increasing awareness and diagnosis of cervical dystonia: The awareness and recognition of cervical dystonia as a distinct neurological disorder has improved in recent years, leading to more accurate and timely diagnosis of the condition. This has resulted in increased demand for treatment and support services for patients with cervical dystonia. Moreover, the availability of diagnostic tools such as electromyography (EMG) and genetic testing has facilitated the identification and classification of cervical dystonia subtypes, which may help in tailoring the treatment to individual needs and preferences.
• Rising demand for botulinum toxin injections: Botulinum toxin injections are the mainstay of treatment for cervical dystonia, as they can reduce muscle spasms and improve the posture and quality of life of the patients. Botulinum toxin injections are available in four types: A (Botox, Dysport, Xeomin), B (Myobloc, Neurobloc), C, and D. Among them, type A is the most widely used and has the longest duration of action. The global botulinum toxin market was valued at USD 4.7 billion in 2019 and is expected to grow at a CAGR of 7.5% from 2020 to 2027, driven by the increasing applications of botulinum toxin in various therapeutic and cosmetic areas, including cervical dystonia.
• Development of novel therapies and devices: Besides botulinum toxin injections, there are several other therapies and devices that are being developed or investigated for the treatment of cervical dystonia. These include oral medications such as dopamine agonists, anticholinergics, benzodiazepines, and cannabinoids; intrathecal baclofen pumps; deep brain stimulation (DBS); transcranial magnetic stimulation (TMS); and ultrasound-guided percutaneous radiofrequency ablation. These therapies and devices aim to provide more effective, safe, and convenient options for patients with cervical dystonia who are refractory to or intolerant of botulinum toxin injections or oral medications.
• Growing geriatric population: The prevalence of cervical dystonia increases with age, and the condition is more common in older adults than in younger ones. According to the World Health Organization (WHO), the global population aged 60 years and over was 962 million in 2017 and is expected to double to 2.1 billion by 2050. As the aging population grows, so does the potential market for cervical dystonia treatment, as more people may develop or seek treatment for the condition.
• High cost of treatment: The treatment of cervical dystonia can be expensive, especially for botulinum toxin injections and surgical procedures. The average cost of a single botulinum toxin injection for cervical dystonia in the US ranges from USD 300 to USD 600, depending on the dose and type of botulinum toxin used. The cost of DBS surgery for cervical dystonia can range from USD> 50,000 to USD 100,000, depending on the location and complexity of the procedure. These costs may pose a significant burden for patients and their families, especially in low- and middle-income countries, where access to affordable and quality health care is limited.
• Adverse effects of medications and injections: The medications and injections used for cervical dystonia can cause various side effects, such as dry mouth, nausea, drowsiness, headache, pain, swelling, bruising, infection, weakness, dysphagia, and dysphonia. In some cases, these side effects can be severe or life-threatening, such as allergic reactions, botulinum toxin spread, or hemorrhage. These side effects may affect the compliance and satisfaction of the patients and limit the use of certain medications and injections for cervical dystonia treatment.
• Lack of reimbursement policies: The reimbursement policies for cervical dystonia treatment vary widely across different countries and regions, and often depend on the type and severity of the condition, the availability and efficacy of the treatment, and the insurance coverage and regulations. In some countries, such as the US, Canada, and Australia, botulinum toxin injections are covered by public or private health insurance plans for cervical dystonia, but the coverage may be partial or subject to certain conditions and limitations. In other countries, such as India, China, and Brazil, botulinum toxin injections are not covered by any health insurance plans and have to be paid out-of-pocket by the patients. The lack of reimbursement policies may deter some patients from seeking or continuing treatment for cervical dystonia, especially if they have low income or limited resources.

Cervical Dystonia Market Trends and Developments

• Emergence of gene therapy:

Phase I clinical trial of AXO-AAV-GM2, developed by Axovant Gene Therapies, to evaluate safety and efficacy in patients with cervical dystonia. Expected to enroll 12 patients and complete by 2023.

• Launch of new devices and technologies

In 2020, Medtronic received FDA approval for its Percept PC neurostimulator, a DBS device that can monitor and record brain signals while delivering electrical stimulation to targeted areas. Indicated for the treatment of cervical dystonia, among other neurological disorders.

• Expansion of botulinum toxin market

Key factors driving market growth include increasing demand for cosmetic and therapeutic applications, approval of new products and indications, and rising disposable income and medical tourism.

Cervical Dystonia Market Segmentation
Market Breakup by Type

• Retrocollis
• Anterocollis
• Laterocollis
• Torticollis
• Others

Market Breakup by Therapy

• Oral Therapy
• Intravenous
• Surgery
• Others

Market Breakup by End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• China

Cervical Dystonia Market Competitive Landscape
The key players in the market include AbbVie Inc., Ipsen Pharma, Galderma SA, Revance Therapeutics Inc., AEON Biopharma, Merz Pharmaceuticals, US World Meds, Tercica Inc., Boston Scientific Corporation, Allergan Inc., and Solstice neurosciences lnc. These players are engaged in various strategies, such as product launches and approvals, mergers and acquisitions, collaborations and partnerships, research and development, and expansion, to gain a competitive edge and increase their market share.


This product will be delivered within 5-7 business days.